Boehringer Ingelheim Corporate News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.empa-reg-outcome-recurrent-events
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME ® trialIn new results published in The Lancet Diabetes& Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular diseaseRecurrent cardiovascular events in people with type 2 diabetes are responsible for considerable clinical and socioeco...
Source: Boehringer Ingelheim Corporate News - November 18, 2020 Category: Research Source Type: news
Positive-CHMP-opinion-for-dabigatran-in-children
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa ® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of ageNo approved therapy for the treatment and prevention of venous thromboembolic events in children until nowCurrent standard of care often associated with frequent monitoring of anticoagulation or daily injections1Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran ´s established and well-documented safety and efficacy prof...
Source: Boehringer Ingelheim Corporate News - November 13, 2020 Category: Research Source Type: news
new_analysis_nintedanib_SSc_ILD
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1 Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS ® trial, according to this analysis1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2020 Category: Research Source Type: news
Developing-potential-treatment-for-severe-COVID
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news
Developing-potential-treatment-for-severe-COVID19-complications
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 tri...
Source: Boehringer Ingelheim Corporate News - October 28, 2020 Category: Research Source Type: news
Boehringer Ingelheim Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigsThis novel device will bring benefits to swine producers ensuring improved safety and efficacy of vaccinationForming new partnerships is fully aligned with part of Boehringer Ingelheim ’s animal health strategy, aiming to accelerate innovation and growth (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 23, 2020 Category: Research Source Type: news
Purevax range now available in 0.5 ml presentation
Purevax ® range now available in 0.5 ml presentationBoehringer Ingelheim announces reduced volume vaccines for catsMore convenient vaccination experience combined with same efficacyPurevax ® is the only fully adjuvant‑free feline vaccine range (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the ClinicThe collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim ’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading asse ts in cancer immunology. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 14, 2020 Category: Research Source Type: news
Advance study vaccinating increased milk production
New ADVANCE study shows vaccinating results in increased milk productionThe ADVANCE1 study demonstrates benefits of vaccinationBoehringer Ingelheim remains committed to bringing new findings to its customers through continuous research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 5, 2020 Category: Research Source Type: news
Advance study shows vaccinating results in increased milk production
New ADVANCE study shows vaccinating results in increased milk productionThe ADVANCE1 study demonstrates benefits of vaccinationBoehringer Ingelheim remains committed to bringing new findings to its customers through continuous research (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 5, 2020 Category: Research Source Type: news
Winners of the 2020 European PRRS Research Award
announcedBoehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro eachThe company sponsored the annual European PRRS Awards for the seventh time (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 1, 2020 Category: Research Source Type: news
Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaborationThis partnership aims to develop sustainable animal health productsBoehringer Ingelheim continues to strive to minimize the environmental footprint of its operations and products (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 30, 2020 Category: Research Source Type: news
Partnership to further develop pet market in China
Boehringer Ingelheim invests to further develop the pet care market in ChinaBoehringer Ingelheim has acquired an equity stake in New Ruipeng Group (NRP Group) which operates digital and clinical pet services across China The partnership with NRP Group aims to expand health solutions, quality advice and professional care to the growing number of pets and pet owners in China (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 29, 2020 Category: Research Source Type: news
World Rabies Day 2020 sustainable dog vaccination
Boehringer Ingelheim steps up its efforts to eliminate rabies through sustainable programs Vaccinating dogs most effective to protect human lives Boehringer Ingelheim supports local self-sustaining programs that fight rabies Contributing to continuous rabies awareness and vaccination campaigns key to the company ’s strategy (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2020 Category: Research Source Type: news
clinical_collaboration_with_Mirati
BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patientsStudy is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 17, 2020 Category: Research Source Type: news
